David Teira

Jesús Zamora Bonilla, profesor de la Universidad Carlos III, es un autor bien conocido para el lector de Theoria por sus publicaciones en filosofía general de las ciencias y en filosofía de la economía. Sólo su distribuidora es culpable de que muchos lectores ignoren aún su primer libro, Mentiras a medias, un amplio estudio de la idea de verosimilitud que incluye una propuesta original, ya discutida en foros internacionales. El trabajo en epistemología general de las ciencias que aquí presentamos se articula, además, con sus aportaciones a la economía de la ciencia y a la propia reconstrucción racional de la metodología económica. No está de más, por tanto, el volver sobre los fundamentos de este proyecto, pues, como es sabido, no son pocas las dificultades que ofrece el concepto de verosimilitud.

Debiasing procedures are experimental methods aimed at correcting errors arising from the cognitive biases of the experimenter. We discuss two of these methods, the predesignation rule and randomization, showing to what extent they are open to the experimenter’s regress: there is no metarule to prove that, after implementing the procedure, the experimental data are actually free from biases. We claim that, from a contractarian perspective, these procedures are nonetheless defensible since they provide a warrant of the impartiality of the experiment: we only need proof that the result has not been intentionally manipulated for prima facie acceptance

I will open the first part of this paper by trying to elucidate the frequentist foundations of RCTs. I will then present a number of methodological objections against the viability of these inferential principles in the conduct of actual clinical trials. In the following section, I will explore the main ethical issues in frequentist trials, namely those related to randomisation and the use of stopping rules. In the final section of the first part, I will analyse why RCTs were accepted for regulatory purposes. I contend that their main virtue, from a regulatory viewpoint, is their impartiality, which is grounded in randomisation and fixed rules for the interpretation of the experiment. Thus the question will be whether Bayesian trials can match or exceed the achievements of frequentist RCTs in all these respects. In the second part of the paper, I will first present a quick glimpse of the introduction of Bayesianism in the field of medical experiments, followed by a summary presentation of the basic tenets of a Bayesian trial. The point here is to show that there is no such thing as “a” Bayesian trial. Bayesianism can ground many different approaches to medical experiments and we should assess their respective virtues separately. Thus I present two actual trials, planned with different goals in mind, and assess their respective epistemic, ethical and regulatory merits. In a tentative conclusion, I contend that, given the constraints imposed by our current regulatory framework, impartiality should preside over the design of clinical trials, even at the expense of many of their inferential and ethical virtues.

Did the impartiality of clinical trials play any role in their acceptance as regulatory standards for the safety and efficacy of drugs? According to the standard account of early British trials in the 1930s and 1940s, their impartiality was just rhetorical: the public demanded fair tests and statistical devices such as randomization created an appearance of neutrality. In fact, the design of the experiment was difficult to understand and the British authorities took advantage of it to promote their own particular interests. I claim that this account is based on a poorly defined concept of experimental fairness . I present an alternative approach in which a test would be impartial if it incorporates warrants of non-manipulability. With this concept, I reconstruct the history of British trials showing that they were indeed fair and this fairness played a role in their acceptance as regulatory yardsticks

Why scientists reach an agreement on new experimental methods when there are conflicts of interest about the evidence they yield? I argue that debiasing methods play a crucial role in this consensus, providing a warrant about the impartiality of the outcome regarding the preferences of different parties involved in the experiment. From a contractarian perspective, I contend that an epistemic pre-requisite for scientists to agree on an experimental method is that this latter is neutral regarding their competing interests. I present two medical experiments (on smallpox inoculation and Mesmerism) in which debiasing procedures such as blinding and data tabulation provided warrants of impartiality that made people agree on the experimental design even if they disagreed on the outcome.

In this article we explore an argumentative pattern that provides a normative justification for expected utility functions grounded on empirical evidence, showing how it worked in three different episodes of their development. The argument claims that we should prudentially maximize our expected utility since this is the criterion effectively applied by those who are considered wisest in making risky choices (be it gamblers or businessmen). Yet, to justify the adoption of this rule, it should be proven that this is empirically true: i.e. that a given function allows us to predict the choices of that particular class of agents. We show how expected utility functions were introduced and contested in accordance with this pattern in the 18th century and how it recurred in the 1950s when Allais made his case against the neo-Bernoullians